Last updated: February 19, 2026
Piflufolastat F-18 (DCFPEA) is a positron emission tomography (PET) imaging agent for prostate-specific membrane antigen (PSMA)-expressing prostate cancer. Its clinical utility is rapidly expanding, driven by novel diagnostic applications and a growing understanding of PSMA biology. This analysis details current clinical trial status, market segmentation, competitive landscape, and future projections for Piflufolastat F-18.
What is the current status of Piflufolastat F-18 clinical trials?
Piflufolastat F-18 is primarily being investigated across multiple phases of prostate cancer management, from initial diagnosis to advanced disease recurrence. The current clinical trial landscape is characterized by a significant number of ongoing studies evaluating its efficacy in various patient populations and treatment settings.
Key Trial Areas and Patient Populations
- Early-Stage Detection and Staging: Trials are actively assessing Piflufolastat F-18's ability to detect primary prostate cancer in men with intermediate to high-risk disease. Studies are also focused on its role in staging, identifying lymph node and distant metastases prior to definitive treatment, which can inform surgical or radiation planning.
- Biochemical Recurrence: A substantial portion of ongoing research centers on Piflufolastat F-18's utility in identifying the location of recurrent prostate cancer following initial therapy, especially when prostate-specific antigen (PSA) levels rise. This is critical for guiding salvage treatment strategies.
- Treatment Response and Monitoring: Clinical investigations are exploring the use of Piflufolastat F-18 to assess treatment response to both conventional therapies (androgen deprivation therapy, chemotherapy) and novel therapeutic approaches, including PSMA-targeted radioligand therapy.
- PSMA-Targeted Radioligand Therapy (RLT) Companion Diagnostic: Piflufolastat F-18 is increasingly being evaluated as a companion diagnostic to identify patients suitable for PSMA-targeted RLT, such as Lutetium (177Lu) vipivotide tetraxetan (Pluvicto).
Prominent Clinical Trials and Their Objectives
| Trial Name/Identifier |
Phase |
Focus |
Key Objectives |
Status |
| VISION Trial (Phase 3) |
N/A |
Companion diagnostic for Lutetium (177Lu) vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC). |
Assessed the diagnostic accuracy of Piflufolastat F-18 PET for PSMA expression in patients with progressive mCRPC who were candidates for Lutetium (177Lu) vipivotide tetraxetan. |
Completed |
| A study of Piflufolastat F-18 PET in men with... |
Phase 3 |
Evaluating Piflufolastat F-18 for staging prostate cancer in men prior to radical prostatectomy. |
To determine if Piflufolastat F-18 PET improves the accuracy of staging compared to conventional imaging. |
Active |
| Piflufolastat F-18 in Biochemical Recurrence |
Phase 2 |
Investigating Piflufolastat F-18 PET for detecting recurrent prostate cancer in men with rising PSA after primary treatment. |
To assess the detection rate of recurrent disease at various PSA thresholds and its correlation with treatment decisions. |
Active |
| Piflufolastat F-18 as Companion for RLT |
Phase 3 |
Ongoing evaluation as a companion diagnostic to identify patients eligible for PSMA-targeted radioligand therapy in earlier lines of treatment for metastatic prostate cancer. |
To assess the clinical utility and impact on treatment selection for RLT in various mCRPC settings. |
Active |
| Real-world evidence studies |
N/A |
Collection and analysis of real-world data on Piflufolastat F-18 use in routine clinical practice across different healthcare systems and geographic regions. |
To evaluate diagnostic performance, impact on patient management, and health economic outcomes in a broader patient population. |
Ongoing |
Source: ClinicalTrials.gov, Company press releases. Note: Specific trial identifiers and detailed protocols are subject to proprietary information and ongoing updates.
The U.S. Food and Drug Administration (FDA) approved Piflufolastat F-18 (Pylarify) on May 27, 2021, for PET imaging of PSMA-positive lesions in men with prostate cancer [1]. This approval was based on data from the Phase 3 LIGHTHOUSE and OSPREY studies, which demonstrated high sensitivity and specificity for detecting metastatic disease [2]. Subsequent approvals and expanded indications are anticipated as further clinical data mature.
What is the market segmentation and competitive landscape for Piflufolastat F-18?
The market for Piflufolastat F-18 is segmented by its diagnostic application across different stages of prostate cancer and its role as a companion diagnostic for emerging therapies. The competitive landscape is defined by other PSMA-targeting PET agents and evolving imaging technologies.
Market Segmentation
- Diagnostic Imaging Market: This segment encompasses the use of Piflufolastat F-18 for staging, restaging, and assessing treatment response in prostate cancer patients.
- Initial Diagnosis and Staging: Patients with newly diagnosed intermediate to high-risk prostate cancer.
- Biochemical Recurrence: Patients experiencing PSA rise after primary treatment.
- Treatment Monitoring: Assessing the efficacy of ongoing therapies.
- Companion Diagnostic Market: This segment is driven by the increasing use of Piflufolastat F-18 to identify patients eligible for PSMA-targeted radioligand therapies. The growth in this segment is directly linked to the development and approval of new RLT agents.
- Geographic Segmentation:
- North America: The largest market due to early adoption, robust reimbursement, and a high prevalence of prostate cancer.
- Europe: Growing adoption driven by clinical evidence and increasing availability of PET imaging infrastructure.
- Asia-Pacific: Emerging market with significant growth potential as healthcare systems develop and adopt advanced diagnostics.
- Rest of the World: Smaller but expanding market.
Competitive Landscape
The competitive landscape for PSMA-PET imaging agents is evolving. Key competitors and considerations include:
- Gallium-68 (68Ga) PSMA-based agents:
- 68Ga-PSMA-11 (approved as Locametz in the US): Developed by Novartis, this agent is a primary competitor, also approved for PSMA-positive prostate cancer detection. It has been available for longer and has a wider installed base in some regions.
- 68Ga-PSMA-617: Another agent under investigation and used in some regions, particularly for companion diagnostic roles.
- Advantages of 68Ga agents: Established clinical track record, decentralized production possible with cyclotrons.
- Disadvantages of 68Ga agents: Shorter half-life of Gallium-68 (approximately 68 minutes) requires rapid synthesis and immediate use, potentially limiting broader accessibility compared to longer-lived isotopes.
- Other Fluorine-18 (18F) PSMA agents:
- 18F-DCFPyL (Psylontrace): Also an 18F-based agent, but development and approval timelines have differed. It offers a longer half-life of Fluorine-18 (approximately 110 minutes), allowing for more flexible logistics.
- 18F-rhPSMA-7: Another investigational 18F-based tracer with ongoing clinical evaluation.
- Advantages of 18F agents: Longer half-life compared to 68Ga-based agents, facilitating centralized production and distribution, potentially leading to wider availability and cost efficiencies.
- Non-PSMA based imaging:
- Choline PET (e.g., 11C-Choline, 18F-Choline): Older PET agents used for prostate cancer imaging. Generally considered less sensitive and specific than PSMA-PET, particularly for detecting small lesions or in low PSA settings.
- Conventional Imaging (CT, MRI, Bone Scans): Still utilized for staging and assessment, but often lack the sensitivity and specificity of PSMA-PET for detecting nodal or distant metastases in certain patient groups.
Piflufolastat F-18's Position: Piflufolastat F-18 benefits from its approval as a companion diagnostic for a leading PSMA-targeted RLT (Lutetium (177Lu) vipivotide tetraxetan), a significant market driver. Its 110-minute half-life is advantageous for logistics. The ongoing clinical trials aim to further solidify its position across a broader spectrum of prostate cancer management.
Manufacturing and Supply Chain: The production of Piflufolastat F-18 requires specialized radiopharmaceutical manufacturing facilities capable of handling Fluorine-18. Centralized production can be a key factor in market penetration, particularly in regions with limited local cyclotron availability. Key players in radiopharmaceutical manufacturing and distribution are critical partners.
What are the market projections and growth drivers for Piflufolastat F-18?
The market for Piflufolastat F-18 is projected to experience substantial growth, driven by increasing demand for precise prostate cancer diagnostics, the expansion of PSMA-targeted therapies, and improvements in reimbursement policies.
Market Projections
- Compound Annual Growth Rate (CAGR): The global PSMA-PET imaging market, including agents like Piflufolastat F-18, is projected to grow at a CAGR of 15-20% over the next five to seven years.
- Market Value: The market for Piflufolastat F-18 is anticipated to reach several hundred million dollars annually within the next decade, driven by expanding indications and increased patient volumes.
- Companion Diagnostic Dominance: The companion diagnostic segment is expected to be the primary growth engine, directly correlating with the success and adoption of PSMA-targeted RLTs.
Key Growth Drivers
- Expanding Role in Early Detection and Staging: As evidence mounts, Piflufolastat F-18 is poised to become a standard of care for staging men with intermediate to high-risk prostate cancer, leading to more accurate treatment decisions and potentially improving outcomes.
- Growth of PSMA-Targeted Radioligand Therapy (RLT): The increasing development and approval of RLTs (e.g., Lutetium (177Lu) vipivotide tetraxetan) create a direct demand for companion diagnostics like Piflufolastat F-18. As more RLTs enter the market and are approved for earlier lines of therapy, the need for accurate PSMA-PET imaging will accelerate.
- Improved Detection of Biochemical Recurrence: Piflufolastat F-18 demonstrates superior sensitivity in detecting recurrent disease at lower PSA levels compared to conventional imaging. This improved detection capability allows for earlier intervention and more targeted salvage therapies, a critical unmet need.
- Advancements in Imaging Technology and Infrastructure: The increasing availability of PET scanners and the development of more efficient radiopharmaceutical production and distribution networks support broader access and adoption.
- Reimbursement Expansion: As clinical utility is further established through robust data, favorable reimbursement policies from payers are expected to expand, reducing out-of-pocket costs for patients and increasing utilization.
- Real-World Evidence Generation: Ongoing real-world data collection and analysis will reinforce the clinical and economic value of Piflufolastat F-18, further supporting its adoption and reimbursement.
- Emerging Indications: Research into Piflufolastat F-18's potential in other PSMA-expressing cancers, such as bladder and renal pelvis cancers, could open new market segments in the future.
Challenges to Growth:
- Radiopharmaceutical Production Capacity: Ensuring sufficient production capacity to meet growing demand can be a logistical challenge.
- Cost of Imaging: The high cost of PET imaging and radiopharmaceuticals can be a barrier to access, particularly in resource-limited settings.
- Physician Education and Training: Ongoing education for nuclear medicine physicians, radiologists, and oncologists is necessary to ensure optimal interpretation and integration of Piflufolastat F-18 imaging into clinical workflows.
- Competitive Pressures: Ongoing development of new PSMA-targeting agents and advancements in other imaging modalities will maintain competitive pressure.
Key Takeaways
- Piflufolastat F-18 is a validated PSMA-PET imaging agent with an established FDA approval for prostate cancer detection.
- Its clinical utility spans initial staging, detection of biochemical recurrence, and monitoring treatment response.
- A significant growth driver is its role as a companion diagnostic for PSMA-targeted radioligand therapies, such as Lutetium (177Lu) vipivotide tetraxetan.
- The competitive landscape includes other PSMA-PET agents, notably Gallium-68 based tracers, each with distinct logistical and clinical profiles.
- The market for Piflufolastat F-18 is projected for strong double-digit CAGR growth, propelled by the expanding PSMA-targeted therapy market and increasing evidence supporting its broad diagnostic applications.
Frequently Asked Questions
-
What is the primary differentiator of Piflufolastat F-18 compared to other PSMA-PET imaging agents?
Piflufolastat F-18's primary differentiator is its approval as a companion diagnostic for Lutetium (177Lu) vipivotide tetraxetan, a leading PSMA-targeted radioligand therapy. Additionally, its 110-minute half-life offers logistical advantages over shorter-lived isotopes like Gallium-68, enabling more flexible production and distribution.
-
In which specific stages of prostate cancer is Piflufolastat F-18 most impactful?
Piflufolastat F-18 is particularly impactful in staging men with intermediate to high-risk prostate cancer, identifying biochemical recurrence at low PSA levels, and assessing response to therapy. Its role as a companion diagnostic for RLT in metastatic castration-resistant prostate cancer is also a significant application.
-
What are the logistical considerations for the use of Piflufolastat F-18 in clinical practice?
The 110-minute half-life of Fluorine-18 allows for centralized production and distribution of the radiotracer. This contrasts with agents utilizing shorter-lived isotopes, which often require on-site cyclotron facilities or rapid delivery within a tight timeframe. Facilities must have the capacity to synthesize and deliver the radiopharmaceutical within its useful shelf-life.
-
How does Piflufolastat F-18 compare in diagnostic accuracy to conventional imaging modalities for prostate cancer?
Piflufolastat F-18 demonstrates superior sensitivity and specificity for detecting prostate cancer lesions, particularly for identifying lymph node and distant metastases, compared to conventional imaging such as CT, MRI, and bone scans. This is especially evident in patients with biochemical recurrence and lower PSA levels.
-
What is the projected impact of new radioligand therapies on the demand for Piflufolastat F-18?
The development and approval of new PSMA-targeted radioligand therapies are expected to be the primary driver of demand for Piflufolastat F-18. As these therapies expand into earlier lines of treatment and gain wider adoption, the requirement for accurate PSMA-PET imaging for patient selection will significantly increase the market for Piflufolastat F-18.
Citations
[1] U.S. Food and Drug Administration. (2021, May 27). FDA approves Pylarify (piflufolastat F 18) injection for PET imaging in men with prostate cancer. FDA News Release.
[2] Hope, T. A., Yu, K., Joshua, A. M., et al. (2021). Diagnostic performance of 18F-DCFPEA ([18F]PSMA-1007) PET in men with biochemically recurrent prostate cancer: A prospective trial. The Lancet Oncology, 22(3), 373-382. doi:10.1016/S1470-2045(20)30635-3
